Intelligencia AI

Intelligencia AI uses artificial intelligence to de-risk drug development. Our platform focuses on estimating the risk of clinical trials, and interpreting the multitude of factors that contribute to that risk. We bridge the gap between innovation and risk reduction, with the ultimate goal of bringing novel therapies to patients faster. Our interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers combines and interprets disparate data across the life scien[1][2]

Visit website Suggest an update

2017 Founded

Overview

Intelligencia AI is listed as a New York City artificial intelligence company[1] operating in the enterprise AI sector[1]. The company uses artificial intelligence to de-risk drug development[2]. Its platform focuses on estimating the risk of clinical trials and interpreting the multitude of factors that contribute to that risk[2]. According to the company, it bridges the gap between innovation and risk reduction, with the goal of bringing novel therapies to patients faster[2]. The company's interdisciplinary team comprises software engineers, AI practitioners, scientists, and drug developers who combine and interpret disparate data across the life sciences[2]. As of available records, Intelligencia AI has 114 employees[3] and operates in the software development industry[3].

Business address: 160 Varick St, New York, New York, 10013. [7]

Growth & traction

LinkedIn lists 114 people working at Intelligencia AI. [4]

Something wrong or missing? Send an update. Fixed within 24 hours.